Merck Gains FDA Approval for First OTC Patch for Overactive Bladder

The FDA has approved Merck's (NYSE: MRK  ) Oxytrol for Women, the first over-the-counter treatment for overactive bladder in women, a condition that Merck says affects more than 20 million American women.

Overactive bladder is characterized by a strong urge to urinate right away and the need to urinate more often. It typically affects women between the ages of 45 and 60.

Oxytrol was previously a prescription-only patch, but Merck convinced the FDA that it was safe enough for over-the-counter status. The company ran a series of studies to prove that women could correctly diagnose that they have overactive bladder and that they could use the patch correctly unsupervised.

Merck licensed Oxytrol as an over-the-counter treatment for overactive bladder from Watson Pharmaceuticals, now known as Actavis (NYSE: ACT  ) . Oxytrol will remain as a prescription drug for the treatment of overactive bladder in men.

link


Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2216603, ~/Articles/ArticleHandler.aspx, 9/17/2014 5:59:50 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement